Shares Magazine
1.90p+0.20 (+11.76%)21 Nov 2024, 15:38
Jump to:
Cizzle Biotechnology Holdings PLC Fundamentals
| Company Name | Cizzle Biotechnology Holdings PLC | Last Updated | 2024-11-21 |
|---|---|---|---|
| Industry | Biotechnology | Sector | Healthcare |
| Shares in Issue | 396.392 m | Market Cap | £7.53 m |
| PE Ratio | 1.68 | Dividend per Share | 0 |
| Dividend Yield | 0 | Dividend Cover | 0 |
| EPS | -£0.01 | EPS Growth (%) | 0 |
| PEG | 0 | DPS Growth (%) | 0 |
| Debt Ratio | 0 | Debt Equity Ratio | 0 |
| Asset Equity Ratio | 1.1625 | Cash Equity Ratio | 1.0277 |
| Quick Ratio | 7.1550 | Current Ratio | 7.16 |
| Price To Book Value | 8.4890 | ROCE | 0 |
Cizzle Biotechnology Holdings PLC Dividends
| Type | Ex-Date | Pay Date | Currency | Net Dividend | Year Total |
|---|
Cizzle Biotechnology Holdings PLC Company Financials
| Assets | 2023 | 2022 | 2021 |
|---|---|---|---|
| Tangible Assets | 0 | 0 | 0 |
| Intangible Assets | 0 | £2.08 m | £200,000.00 |
| Investments | 0 | 0 | 0 |
| Total Fixed Assets | 0 | £2.08 m | £200,000.00 |
| Stocks | 0 | 0 | 0 |
| Debtors | £27,000.00 | £132,000.00 | £29,000.00 |
| Cash & Equivalents | £1.56 m | £478,000.00 | £875,000.00 |
| Other Assets | 0 | 0 | 0 |
| Total Assets | £1.69 m | £2.79 m | £1.16 m |
| Liabilities | 2023 | 2022 | 2021 |
|---|---|---|---|
| Creditors within 1 year | £186,000.00 | £145,000.00 | £218,000.00 |
| Creditors after 1 year | 0 | 0 | 0 |
| Other Liabilities | 0 | 0 | 0 |
| Total Liabilities | £186,000.00 | £145,000.00 | £218,000.00 |
| Net assets | £1.51 m | £2.64 m | £937,000.00 |
| Equity | 2023 | 2022 | 2021 |
|---|---|---|---|
| Called up share capital | £37,000.00 | £35,000.00 | £26,000.00 |
| Share Premium | £35.34 m | £34.92 m | £32.57 m |
| Profit / Loss | -£1.76 m | -£963,000.00 | -£3.96 m |
| Other Equity | £1.51 m | £2.64 m | £937,000.00 |
| Preference & Minorities | 0 | 0 | 0 |
| Total Capital Employed | £1.51 m | £2.64 m | £937,000.00 |
| Ratios | 2023 | 2022 | 2021 |
|---|---|---|---|
| Debt Ratio | 0 | 0 | 0 |
| Debt-to-Equity | 0 | 0 | 0 |
| Assets / Equity | 1.1625 | 1.1625 | 1.1625 |
| Cash / Equity | 1.0277 | 1.0277 | 1.0277 |
| EPS | £-0.00 | £-0.00 | £-0.00 |
| Cash Flow | 2023 | 2022 | 2021 |
|---|---|---|---|
| Cash from operating activities | -£639,000.00 | -£872,000.00 | -£1.01 m |
| Cashflow before financing | -£334,000.00 | -£277,000.00 | £1.02 m |
| Increase in Cash | -£334,000.00 | -£397,000.00 | £868,000.00 |
| Income | 2023 | 2022 | 2021 |
|---|---|---|---|
| Turnover | 0 | 0 | 0 |
| Cost of sales | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 |
| Operating Profit | -£1.76 m | -£963,000.00 | -£3.96 m |
| Pre-Tax profit | -£1.76 m | -£963,000.00 | -£3.96 m |
Cizzle Biotechnology Holdings PLC Company Background
| Sector | Healthcare |
|---|---|
| Activities | Cizzle Biotechnology Holdings PLC is in the early stages of developing a blood test for the early detection of a majority of the different forms of lung cancer. Its proof-of-concept prototype test is based on the ability to detect a stableplasma biomarker, a variant of C1Z1 known as CIZ1B. C1Z1 is a naturally occurring cell nuclear protein involved in DNA replication, and the targeted C1Z1B variant is correlated with early stage lung cancer. |
| Latest Interim Date | 30 Sep 2024 |
| Latest Fiscal Year End Date | 27 Apr 2023 |
Cizzle Biotechnology Holdings PLC Directors
| Appointed | Name | Position |
|---|---|---|
| 2011-08-09 | Mr. John Corelli James Thynne | Non-Executive Director |
| 2011-08-09 | Mr. Gareth Jones | Executive Director,Chief Technology Officer |
| 2019-04-30 | Mr. Jonathan David Freeman | Non-Executive Director,Chairman |
| 2011-08-09 | Mr. Simon John Gibson OBE | Non-Executive Director |
| 2016-05-31 | Dr. Andrew William Nelson OBE | Non-Executive Director |
| 2011-08-09 | Mr. Owen Griffith Ronald Jones | Non-Executive Director |
| 2011-08-09 | Mr. Giles Alexander Davies | Executive Director,Chief Financial Officer and Co Secretary |
| 2012-06-27 | Mr. Ceri Jones | Executive Director,Chief Financial Officer and Company Sec |
| 2024-04-30 | Dr. Allan John Syms | Executive Director,Chairman |
| 2011-08-09 | Mr. Shaun Piers Oxenham | Executive Director,Chairman |
| 2019-07-04 | Dr. James Stuart Mckenzie | Executive Director,Chief Executive Officer |
| 2019-07-04 | Dr. Majid Zoorob | Executive Director,Chief Technical Officer |
| 2015-11-20 | Mr. Russell Anthony Banks | Executive Director,Chief Financial Officer |
| 2016-06-23 | Mr. Philip Antony Marshall | Non-Executive Director |
| 2024-04-30 | Mr. John Michael Treacy | Non-Executive Director |
| 2024-04-30 | Mr. Dawn Alison Coverley | Non-Executive Director |
| 2024-04-30 | Mr. Nigel Ronald Lee | Executive Director,Finance Director |
Cizzle Biotechnology Holdings PLC Contact Details
| Company Name | Cizzle Biotechnology Holdings PLC |
|---|---|
| Address | Heslington Hall, Heslington, York, YO10 5DD |
| Telephone | +44 207264444 |
| Website | https://www.cizzlebiotechnology.com |
Cizzle Biotechnology Holdings PLC Advisors
| Stockbroker | Peterhouse Corporate Finance Ltd |
|---|---|
| Phone | +44 2074690930 |
| Fax | +44 2072209798 |
| Nominated Adviser | Northland Capital Partners |
|---|---|
| Phone | +44 2038616625 |
| Fax | +44 2076005975 |
| Stockbroker | Northland Capital Partners |
|---|---|
| Phone | +44 2038616625 |
| Fax | +44 2076005975 |
| Solicitor | Greenaway Scott LLP |
|---|---|
| Phone | 029 2009 5500 |
| Registrar | Link Asset Services |
|---|---|
| Phone | +44 8716640300 |
| Fax | +44 2086392342 |
| Financial PR Adviser | Instinctif Partners |
|---|---|
| Phone | +44 2074572020 |
| Bank | Barclays Bank PLC |
|---|
Most Read
Receive our
daily news email
Subscribe to the latest investing news by entering your email address below
You can opt out at any time.
For five days a week you will get
- The latest company news
- Insight into investment trends
- Round-up of director's buys and sells
- Articles from Shares magazine
